Royalty Pharma RPRX EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's EBIT?
- Royalty Pharma (RPRX) reported EBIT of $563.04M in Q1 2026.
- How has Royalty Pharma's EBIT changed year-over-year?
- Royalty Pharma's EBIT increased by 5.4% year-over-year, from $534.18M to $563.04M.
- What is the long-term trend for Royalty Pharma's EBIT?
- Over 3 years (2021 to 2025), Royalty Pharma's EBIT has grown at a 2.9% compound annual growth rate (CAGR), from $1.43B to $1.56B.
- What does EBIT mean?
- Profit before interest and taxes — the business's core earning power.
- How do you interpret EBIT?
- Higher is better. Because it adds back interest, EBIT compares earning power across firms with very different debt loads — the base for interest coverage and the EV/EBIT multiple. For filers reporting operating income it equals that line, excluding non-operating swings.
- How does EBIT compare across companies?
- Comparable across companies regardless of leverage or tax domicile; the standard 'earning power' line for cross-company analysis. Least meaningful for banks and insurers.